Debiopharm Group and TCG Lifesciences Ltd. enter into an exclusive research agreement

Debiopharm Group and TCG Lifesciences Ltd. enter into an exclusive research agreement

Lausanne, Switzerland and Kolkata, India  – Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections. Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.

Source: Debiopharm (Link to press release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply